Lexeo Therapeutics, Inc. Common Stock (LXEO) Stock
Key stats
- Market cap
- $252.01M
- Price / Earnings ratio
- -2.9x
- EPS (TTM)
- -$1.02
- Volume
- Loading
- 52-week high
- $10.99
- 52-week low
- $2.55
Source: third-party data provider, as of November 13, 2026
Compare with LXEO
Recent news

Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
LXEO

Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
LXEO

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO
U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO
LXEO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 47.96
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.14
- MACD histogram
- 0.05
- SMA 50
- $3.46
- Price below SMA 50
- EMA 50
- $3.43
- Price below EMA 50
- SMA 200
- $5.04
- Price below SMA 200
- EMA 200
- $5.25
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
LXEO

Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
LXEO

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO
U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO
LXEO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Lexeo Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. R. Nolan Townsend M.B.A. | CEO & Director | 1981 |
| Mr. Louis Tamayo | CFO & Principal Accounting Officer | 1977 |
| Dr. Jose Manuel Otero Ph.D. | Chief Operating Officer | 1979 |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | — |
| Dr. Narinder P. Bhalla FACC, FSCAI, M.D. | Chief Medical Officer | 1964 |
| Mr. Keith Wonnacott | Senior Vice President of Regulatory Affairs | — |
| Ms. Ashley Kaplowitz | Head of Capital Markets | — |
| Mr. Ryan McHenry | VP & Corporate Controller | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.96
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.14
- MACD histogram
- 0.05
- SMA 50
- $3.46
- Price below SMA 50
- EMA 50
- $3.43
- Price below EMA 50
- SMA 200
- $5.04
- Price below SMA 200
- EMA 200
- $5.25
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $15.00
- Average
- $15.00
- High
- $15.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +26.6 | -12.6 | ||||||||||
| 2024 | +15.6 | -13.0 | +5.4 | -21.5 | +35.2 | -5.9 | -19.6 | -11.9 | -20.7 | -9.6 | +3.8 | -21.8 |
| 2025 | -18.6 | -48.5 | +48.3 | +25.6 | -42.3 | +47.8 | +12.1 | +3.9 | +38.6 | +50.8 | +9.1 | +11.3 |
| 2026 | -22.9 | -6.0 | -19.5 | +0.5 | -10.9 | -3.1 | -7.2 | +13.3 | -28.1 | -13.3 | +0.3 |



